Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study
Veterinary Medicine and Science · 2024-05 · 10 (3)
DOI: 10.1002/vms3.1454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary Medicine and Science, online erschienen am 30.04.2024. Verfasst von Ju-Hyun An und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National U…. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Dog Diseases, Insulin, Hypoglycemic Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Regional Innovation Strategy (RIS), National Research Foundation of Korea, Ministry of Education.
Abstract (Originalsprache)
Background
Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors are a novel class of anti‐hyperglycaemic agents.
Objective
This study aimed to evaluate the safety and the adjuvant glycaemic control effect of an SGLT2 inhibitor, DWP16001, in diabetic dogs receiving insulin treatment.
Methods
Nineteen diabetic dogs receiving insulin treatment (NPH, porcine lente and glargine insulin) were divided into two groups according to dosing frequency: DWP TOD group ( n = 10) and DWP SID group ( n = 9). In the DWP TOD group, 0.025 mg/kg of DWP16001 was administered once every 3 days, whereas, in the DWP SID group, 0.025 mg/kg of DWP16001 was administered once a day. Food intake was maintained during the trial period. Hypoglycaemia, ketoacidosis or unexpected life‐threatening reactions were assessed as adverse effects before and after DWP16001 administration. We compared insulin requirement reduction and blood glucose level control between two groups.
Results
No specific adverse effects were observed during the clinical trial, and haematological parameter remained unchanged. Moreover, the fasting glucose levels and daily insulin dose in the DWP TOD group were lower than the pre‐administration values, but not significantly different for 8 weeks. Systolic blood pressure, fructosamine and insulin dose decreased significantly in the DWP SID group compared to the DWP TOD group at 8 weeks ( p < 0.05) without affecting food consumption. Among these patients, 10 patients were monitored while receiving DWP16001 for 12 months (DWP TOD group n = 5, DWP SID group n = 5). The fasting glucose and fructosamine levels and daily insulin dose were reduced in both groups at 12 months compared with those before receiving DWP16001.
Conclusion
When DWP16001, an SGLT2 inhibitor, was supplied to dogs with type 1 diabetes, no adverse effects were observed, and it was confirmed that the administered insulin dose can be reduced in controlling blood glucose.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Veterinary Emergency and Critical Care Medicine and Institute of Veterinary Science, College of Veterinary Medicine, Kangwon National University, Chuncheon-si, Republic of Korea.
- Laboratory of Veterinary Internal Medicine, Department of Veterinary Clinical Science, College of Veterinary Medicine, Seoul National University, Gwanak-gu, Seoul, Republic of Korea.
- Daewoong Pharmaceutical, Life Science Institute, Yongin, Gyeonggi-do, Republic of Korea.
- Department of Veterinary Internal Medicine, College of Veterinary Medicine, Kyungpook National University, Daegu, Republic of Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
- Nowon 24 hours N Animal Medical Center, Nowon-gu, Seoul, Republic of Korea.
ORCID-Profile: Ju-Hyun An, Hyun-Woo Lim, Hwa-Young Youn
Förderung
- Regional Innovation Strategy (RIS)
- National Research Foundation of Korea
- Ministry of Education
- Korea government
- Research Institute for Veterinary Science, Seoul National University
Zitieren
APA
An, J. H., Choi, H. S., Choi, J. S., Lim, H. W., Huh, W., Oh, Y. I., Park, J. S., Han, J., Lim, S., Lim, C. Y., Kim, T. H., Moon, J. B., & Youn, H. Y. (2024). Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study. Veterinary Medicine and Science, 10(3). https://doi.org/10.1002/vms3.1454
Vancouver
An JH, Choi HS, Choi JS, Lim HW, Huh W, Oh YI, et al. Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study. Veterinary Medicine and Science. 2024;10(3). doi:10.1002/vms3.1454
BibTeX
@article{An2024,
author = {An, Ju-Hyun and Choi, Han-Sol and Choi, Ji-Soo and Lim, Hyun-Woo and Huh, Wan and Oh, Ye-In and Park, Joon Seok and Han, Jumi and Lim, Soo and Lim, Chae-Young and Kim, Tae-Hee and Moon, Jae-Bong and Youn, Hwa-Young},
title = {Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot study},
journal = {Veterinary Medicine and Science},
year = {2024},
volume = {10},
number = {3},
doi = {10.1002/vms3.1454}
}
EUVIMED